HOME ·

HUTCHMED

HUTCHMED (00013.HK): Two Phase III Studies Picked for ESMO Orals
Tags：
HUTCHMED00013.HKLung Cancer
2026-09-24
Going Global Weekly Report: Pharma Firms Sealed Licensing Deals at a Fast Pace as Semiconductors and E-Commerce Accelerate toward HK Listings - 20260904
Tags：
Going GlobalMAN WAH HLDGSHUTCHMED
2026-09-04
HUTCHMED (00013.HK): Licenses global rights to KRAS-EGFR antibody-targeted conjugate HMPL-A830 to GSK for up to USD 1.295 billion
Tags：
HUTCHMED00013.HKstrategic cooperation
2026-09-03
HUTCHMED (00013.HK): SANOVO Phase III of ORPATHYS plus TAGRISSO meets primary endpoint in first-line EGFR-mutant NSCLC, with significant PFS benefit
Tags：
HUTCHMED00013.HKClinical Trial
2026-08-31
HUTCHMED (00013.HK): ATLED (Fanregratinib) Approved by NMPA for FGFR2 Fusion Cholangiocarcinoma
Tags：
HUTCHMED00013.HKR&D Progress
2026-08-28
HUTCHMED (00013.HK): ORPATHYS® + TAGRISSO® combination shows statistically and clinically meaningful PFS and OS improvement in MET-driven EGFR-mutated lung cancer
Tags：
HUTCHMED00013.HKClinical Trial
2026-08-17
HUTCHMED(00013.HK): 2026 Interim Report - Profit Attributable to Shareholders stood at USD 15.93 million, YoY decrease of 96.5%
Tags：
HUTCHMED00013.HKInterim Report
2026-07-31
HUTCHMED(00013.HK): ORPATHYS® (Savolitinib) Receives Conditional NMPA Approval for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma with MET Amplification
Tags：
HUTCHMED00013.HKORPATHYSNMPA
2026-07-02
HUTCHMED (00013.HK): Key Phase II Data of Fisogatinib to Be Presented at ESMO Gastrointestinal Cancers Congress
Tags：
HUTCHMED00013.HK
2026-06-25
HUTCHMED (00013.HK): Savolitinib Phase II Gastric Cancer Data Selected for ASCO Rapid Oral Presentation, Achieving an ORR of 32.3%
Tags：
HUTCHMED00013.HKASCO
2026-05-22
HUTCHMED(00013.HK): Sostarlimab Phase III study successful; plans to submit new drug application to NMPA in the first half of 2026
Tags：
HUTCHMED00013.HKSostarlimab
2026-01-07